Canada Markets closed

COMPASS Pathways plc (CMPS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
34.74+0.96 (+2.84%)
At close: 4:00PM EDT
34.74 0.00 (0.00%)
After hours: 05:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close33.78
Open34.50
Bid34.55 x 2900
Ask35.30 x 900
Day's Range33.87 - 35.24
52 Week Range28.58 - 61.69
Volume784,087
Avg. Volume320,216
Market Cap1.425B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.70
Earnings DateMay 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.11
  • GlobeNewswire

    Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

    Investigator-initiated study shows remission in major depression symptoms for 50% of participants London, UK – 20 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients. Within one week of a single administration of COMP360 psilocybin therapy, 50% of parti

  • GlobeNewswire

    COMPASS Pathways is granted new US patent for crystalline psilocybin

    London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted its fourth patent by the US Patent and Trademark Office (USPTO). This is COMPASS’s first patent with claims covering its Form A hydrate psilocybin. The Form A hydrate is distinct from the anhydrate psilocybin for which the company has already been granted eight pa

  • Oilprice.com

    A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector

    One of the world’s largest and most important industries is ripe for disruption, and an under-the-radar artificial intelligence firm is ready to try its luck